Changes in the Anterior Segment and Dry Eye Parameters of People Using Oral Tetracycline

Year 2023, Volume: 5 Issue: 2, 309 - 13, 15.05.2023

Mehmet Tahir Eski , Kuddusi Teberik , Taha Sezer

https://doi.org/10.37990/medr.1226595

Abstract

Aim: The purpose of the study is to evaluate the effect of anti-inflammatory efficiency of tetracycline on dry eye and anterior segment parameters.
Material and Methods: This prospective study was conducted with 61 people who had been using tetracycline for the past 2 months. Each participant went through a detailed ophthalmological examination where intraocular pressure (IOP), central cornea thickness (CCT), K1 and K2 from keratometry measurements, anterior chamber depth (ACD), axial length (AXL), tear breakup time test (BUT), lissamin green staining (LG), Schirmer’s tear test-1 (ST) and ocular surface disease index (OSDI) score were evaluated. Measurements of the patients who would be using a daily dose of 100 mg doxycycline for 2 months were done prior to the medication as well as 1 month and 2 months after the medication. 3 data sets of the participants were compared at the end of 2 months.
Results: When results were compared, it was found that ST and LG parameters gradually increased in the first and second months and this increase was statistically significant (p<0.001 and p=0.018, respectively). On the other hand, BUT and OSDI scores decreased over time but it was not statistically significant. There were no statistically significant differences in terms of other parameters either (p>0.05). When female and male participants were compared in terms of BUT, it was found that the decrease in females at the second month was higher and this was statistically significant (p=0.01).
Conclusion: t was concluded that the young individuals using tetracycline displayed an early stage of improvement in dry eye parameters.

Keywords

Dry eye, tetracycline, anterior segment

References

• Anane S, Mokni M, Beltaief O. [Rosacea-like demodicidosis and chronic blepharitis]. Ann Dermatol Venereol. 2011;138:30–34.
• Onghanseng N, Ng SM, Halim MS, et al. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev. 2021;6:CD013697.
• Dougherty JM, McCulley JP, Silvany RE, et al. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970–5.
• Gudmundsen KJ, O’Donnell BF, Powell FC. Schirmer testing for dry eyes in patients with rosacea. J Am Acad Dermatol. 1992;26:211–4.
• Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49–54.
• Yaylali V, Ozyurt C. Comparison of tear function tests and impression cytology with the ocular findings in acne rosacea. Eur J Ophthalmol. 2002;12:11–7.
• Karalezli A, Borazan M, Yilmaz S, et al. Conjunctival impression cytology and tear-film changes in patients with familial Mediterranean fever. Acta Ophthalmol. 2009;87:39–43.
• Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015;8:544–9.
• Hoeprich PD, Warshauer DM. Entry of four tetracyclines into saliva and tears. Antimicrob Agents Chemother. 1974;5:330-6.
• Gollnick H, Blume-Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8:505–15.
• Kashkouli MB, Fazel AJ, Kiavash V, et al. Oral azithromycin versus doxycycline in meibomian gland dysfunction: a randomised double-masked open-label clinical trial. Br J Ophthalmol. 2015;99:199–204.
• Ozyurt C, Yaylali V, Yıldırım C, et al. The Comparıson Of The Symptoms And Fındıngs Beforeand After Doxycyclıne Therapy In Ocular Rosacea. T Klin J Ophthalmol. 2000;9:107–11.
• Sobolewska B, Doycheva D, Deuter C, et al. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257–60.
• Saá FL, Cremona F, Chiaradia P. Association Between Skin Findings and Ocular Signs in Rosacea. Turk J Ophthalmol. 2021;51:338–43.
• Yoon K-C, Im S-K, Kim H-G, You I-C. Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome. Cornea. 2011;30:972–6.
• Tavassoli S, Wong N, Chan E. Ocular manifestations of rosacea: A clinical review. Clin Exp Ophthalmol. 2021;49:104–17.
• Andrade FMX, Picosse FR, Cunha LP da, et al. Ocular surface changes in the treatment of rosacea: comparison between low-dose oral isotretinoin and doxycycline. Arq Bras Oftalmol. 2020;83:109–12.
• Kılıç Müftüoğlu İ, Aydın Akova Y. Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea. Turk J Ophthalmol. 2016;46: 1–6.
• Frucht-Pery J, Sagi E, Hemo I, et al. Efficacy of doxycycline and tetracycline in ocular rosacea. Am J Ophthalmol. 1993;116:88–92.
• Joffre C, Souchier M, Grégoire S, et al. Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueous-deficient dry eye. Br J Ophthalmol. 2008;92:116–9.
• Bilgin B, Karadag AS. Effects of combined oral doxycycline and topical cyclosporine treatment on ocular signs, symptoms, and tear film parameters in rosacea patients. Arq Bras Oftalmol. 2018;81:466–70.